Molecular basis of colorectal cancer: Towards individualized management?;Bases moleculares del cáncer colorrectal: ¿Hacia un manejo individualizado?

Revista Espanola de Enfermedades Digestivas

Volumn 103, Issue 1, 2011, Pages 29-35

  Perea, J ^a   Lomas, M ^a   Hidalgo, M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Chromosome instability; Colorectal cancer; Methylator phenotype; Microsatellite instability; Mutator phenotype

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MOLECULAR MARKER; PROTEIN BAX; PROTEIN MLH1; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ARTICLE; BAX GENE; CANCER INCIDENCE; CANCER MORTALITY; CHROMOSOMAL INSTABILITY; CHROMOSOME LOSS; COLON CARCINOGENESIS; COLORECTAL CANCER; CPG ISLAND; DOWN REGULATION; GENE; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; MICROSATELLITE INSTABILITY; MLH1 GENE; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; PERSONALIZED MEDICINE; PHENOTYPE; PROGNOSIS; TRANSCRIPTION INITIATION; TREATMENT PLANNING; ADENOCARCINOMA; BIOLOGICAL MODEL; CELL TRANSFORMATION; COLORECTAL TUMOR; DNA METHYLATION; DNA REPAIR; FAMILIAL CANCER; FEMALE; GENETICS; GENOTYPE; INCIDENCE; MALE; ONCOGENE; PATHOLOGY; REVIEW; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA REPAIR; FEMALE; GENES, TUMOR SUPPRESSOR; GENOTYPE; HUMANS; INCIDENCE; INDIVIDUALIZED MEDICINE; MALE; MICROSATELLITE INSTABILITY; MODELS, BIOLOGICAL; NEOPLASTIC SYNDROMES, HEREDITARY; ONCOGENES; PHENOTYPE;

EID: 79960353149     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082011000100006     Document Type: Article

References (32)

1. Béjar Prado LM, Gili M, Ramírez G, et al. Dietary changes and colorectal cancer trends in Spain during 1951-2007. Rev Esp Enferm Dig 2010; 102:159-68.
2. Quintero E, Andréu M, Lanas A, et al. Estrategias para la detección precoz del Cáncer Colorrectal. En: Bandrés F, Castells A, Morillas JD, eds. La prevención del cáncer colorectal en España. Fundación Tejerina, 2009.
3. Fearon ER and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
4. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50:223-30.
5. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet 2010; 375: 1030-47.
6. Ogino S and Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008; 10: 13-27.
7. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004; 23:11-27.
8. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embeded tissue. J Mol Diagn 2006; 8:412-19.
9. Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006; 8:141-51.
10. Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint gnes in human cancers. Nature 1998; 392:300-3.
11. Nishida N, Nagasaka T, Kashiwagi K, et al. High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancer. Cancer Biol Ther 2007; 6:525-33.
12. Fodde R, Kuipers J, Rosenberg C, et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001; 3:433-8.
13. Fodde R, Smits R, Clevers H. APC signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001; 1:55-67.
14. Gualberto A, Aldape K, Kozakiewicz K, et al. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA 1998; 95:5166-71.
15. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260:816-9.
16. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003; 21:1174-9.
17. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248-57.
18. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004; 23:11-27.
19. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268:1336-8.
20. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutador phenotype. Science 1997; 275:967-9.
21. Ogino S, Odze RD, Kawasaki T, et al. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol 2006; 30:1175-83.
22. Snover DC. Update on serrated pathway to colorectal carcinoma. Hum Pathol 2010 Sep 23. [Epub ahead of print].
23. van Rinjsoever M, Grieu F, Eisaleh H, et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002; 51:797-802.
24. Samowitz W, Albertsen H, Herrick J, et al. Evaluation of a large, population- based sample supports a CpG island methylator phenotype (CIMP) in colon cancer. Gastroenterology 2005; 129;837-45.
25. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006; 55:1000-6.
26. Bustamante-Balén M, Bernet L, Cano R, et al. Assessing the reproducibility of the microscopic diagnosis of sessile serrated adenoma of the colon. Rev Esp Enferm Dig 2009; 101:258-64.
27. Ogino S, Kawasaki T, Kirkner GJ, et al. Molecular correlates with MGMT promotermethylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut 2007; 56:1564-71.
28. Ogino S, Kawasaki T, Kirkner GJ, et al. CpG island methylator phenotype- low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006; 8: 582-8.
29. Ogino S, Kawasaki T, Kirkner GJ, et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007; 9:305-14.
30. Di NF, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastasic colorectal cancer. J Clin Oncol 2008; 5705-12.
31. Tejpar S, Bosman F, Delorenzi M, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5-FU-LV or 5FULV and Irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). Proc ASCO Meeting Abstract 2009; 27:4001.
32. Ribic CM, Sargent DJ, Moore DJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-57.